JP2010539192A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539192A5
JP2010539192A5 JP2010525114A JP2010525114A JP2010539192A5 JP 2010539192 A5 JP2010539192 A5 JP 2010539192A5 JP 2010525114 A JP2010525114 A JP 2010525114A JP 2010525114 A JP2010525114 A JP 2010525114A JP 2010539192 A5 JP2010539192 A5 JP 2010539192A5
Authority
JP
Japan
Prior art keywords
vaccine composition
composition according
vlp
norovirus
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010525114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539192A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/076763 external-priority patent/WO2009039229A2/en
Publication of JP2010539192A publication Critical patent/JP2010539192A/ja
Publication of JP2010539192A5 publication Critical patent/JP2010539192A5/ja
Pending legal-status Critical Current

Links

JP2010525114A 2007-09-18 2008-09-18 ノロウイルスに対して防御免疫応答を付与する方法 Pending JP2010539192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97338907P 2007-09-18 2007-09-18
US98682607P 2007-11-09 2007-11-09
PCT/US2008/076763 WO2009039229A2 (en) 2007-09-18 2008-09-18 Method of conferring a protective immune response to norovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014095094A Division JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法

Publications (2)

Publication Number Publication Date
JP2010539192A JP2010539192A (ja) 2010-12-16
JP2010539192A5 true JP2010539192A5 (enExample) 2011-11-04

Family

ID=40468754

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010525114A Pending JP2010539192A (ja) 2007-09-18 2008-09-18 ノロウイルスに対して防御免疫応答を付与する方法
JP2014095094A Active JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法
JP2016149168A Active JP6615063B2 (ja) 2007-09-18 2016-07-29 ノロウイルスに対して防御免疫応答を付与する方法
JP2019107207A Withdrawn JP2019163328A (ja) 2007-09-18 2019-06-07 ノロウイルスに対して防御免疫応答を付与する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014095094A Active JP6296885B2 (ja) 2007-09-18 2014-05-02 ノロウイルスに対して防御免疫応答を付与する方法
JP2016149168A Active JP6615063B2 (ja) 2007-09-18 2016-07-29 ノロウイルスに対して防御免疫応答を付与する方法
JP2019107207A Withdrawn JP2019163328A (ja) 2007-09-18 2019-06-07 ノロウイルスに対して防御免疫応答を付与する方法

Country Status (9)

Country Link
US (5) US10130696B2 (enExample)
EP (1) EP2190471A4 (enExample)
JP (4) JP2010539192A (enExample)
KR (2) KR20150129042A (enExample)
CN (2) CN104740624B (enExample)
AU (1) AU2008302276B2 (enExample)
CA (1) CA2698397C (enExample)
SG (2) SG10201601660YA (enExample)
WO (1) WO2009039229A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577833T3 (es) 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR101793161B1 (ko) 2008-08-08 2017-11-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
WO2010111586A2 (en) 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
US9439958B2 (en) * 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
FI122520B (fi) * 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
CA2829607A1 (en) 2011-03-11 2012-09-20 Mcmaster University A method of vaccination comprising a histone deacetylase inhibitor
EP3299030B1 (en) * 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
AU2012323189A1 (en) * 2011-10-12 2014-03-06 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
CN102559616B (zh) * 2012-02-24 2014-01-01 河南科技大学 一种含诺如病毒rna片段的假病毒颗粒及其制备方法
CA2876495C (en) 2012-06-21 2023-10-17 Northwestern University Peptide conjugated particles
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015017065A (ja) * 2013-07-12 2015-01-29 株式会社Umnファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AU2014329403B2 (en) 2013-10-03 2020-10-08 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
US20160310412A1 (en) 2013-12-16 2016-10-27 Takeda Pharmaceutical Company Limited Microneedle
JP2017507968A (ja) * 2014-03-12 2017-03-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 粘膜送達用のリポソーム組成物
CA3000329A1 (en) 2015-08-28 2017-03-09 Ology Bioservices, Inc. Norovirus vaccine
JP6977206B2 (ja) * 2016-03-31 2021-12-08 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
US11633467B2 (en) 2018-02-15 2023-04-25 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
US20210308249A1 (en) * 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN115677838A (zh) * 2021-07-29 2023-02-03 成都康华生物制品股份有限公司 六价诺如病毒VLPs疫苗及其制备方法
US20250197454A1 (en) 2022-03-18 2025-06-19 Denka Company Limited Virus-like particle containing capsid proteins connected by linker
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) * 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
CA2133339A1 (en) 1992-04-08 1993-10-09 Jennifer S. Rota Wild-type measles virus glycoproteins: vaccine and detection method therefor
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
US5645051A (en) * 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) * 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
IL132201A0 (en) 1997-04-08 2001-03-19 Merck & Co Inc Stabilized human papillomavirus formulations
WO1998050071A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
PL347472A1 (en) * 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
AU770809B2 (en) 1998-12-17 2004-03-04 Merck Sharp & Dohme Corp. Synthetic virus-like particles with heterologous epitopes
KR20010093290A (ko) 1999-02-05 2001-10-27 폴락 돈나 엘. 사람 파필로마바이러스 백신 제제
EP1186890B1 (en) 1999-06-22 2013-01-02 Japan as Represented by Director-General of National Institute of Infectious Diseases Srsv detection kit
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US7041500B2 (en) * 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2486118A1 (en) 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
DE602004020189D1 (de) 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
JP2006518748A (ja) 2003-02-20 2006-08-17 ベクトン・ディキンソン・アンド・カンパニー 改良されたワクチン接種のための大気圧噴霧凍結乾燥によって作製される組換えブドウ球菌エンテロトキシンb(<sb>r</sb>seb)の粉末処方物
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) * 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
US20050152911A1 (en) 2003-09-24 2005-07-14 Montana State University Norovirus monoclonal antibodies and peptides
WO2005037223A2 (en) * 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) * 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
WO2006044857A2 (en) 2004-10-20 2006-04-27 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
EP1846028A4 (en) 2005-01-05 2010-06-30 Philadelphia Health & Educatio TRANSPORT, BIOACTIVE SUBSTANCES AND VIRAL VACCINES
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
PL1868642T3 (pl) 2005-03-18 2013-10-31 Cytos Biotechnology Ag Białka fuzyjne alergenów kocich i ich zastosowania
CN101287489A (zh) 2005-06-01 2008-10-15 陶氏环球技术公司 多价病毒样颗粒的生产
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスgiの高感度検出方法
ES2577833T3 (es) 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR101793161B1 (ko) 2008-08-08 2017-11-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
WO2010084298A1 (en) 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use
ES2552383T3 (es) 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
CA2787666A1 (en) 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2019505498A (ja) 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Nk細胞におけるサイトカイン誘導性sh2タンパク質の阻害
GB2573406B (en) 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
CN112292390A (zh) 2018-05-03 2021-01-29 得克萨斯大学体系董事会 经工程改造以在免疫检查点阻断的情况下表达嵌合抗原受体的自然杀伤细胞
US20210308249A1 (en) 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
EP3924467A1 (en) 2019-02-15 2021-12-22 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy

Similar Documents

Publication Publication Date Title
JP2014141528A5 (enExample)
JP2016020378A5 (enExample)
Riese et al. Vaccine adjuvants: key tools for innovative vaccine design
AU2017203501B2 (en) Vaccine adjuvant composition comprising inulin particles
Kang et al. Application of chitosan microspheres for nasal delivery of vaccines
Sulczewski et al. Nanoparticle vaccines against viral infections
EP2647387B1 (en) Vaccine Composition
Jabbal-Gill Nasal vaccine innovation
JP2011530295A5 (enExample)
EP2257306B1 (en) Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
JP5713672B2 (ja) 結核のワクチンおよびその使用方法
Salvador et al. An overview on the field of micro‐and nanotechnologies for synthetic peptide‐based vaccines
US10857228B2 (en) Adjuvant for vaccines, vaccine, and immunity induction method
JP2010523711A5 (enExample)
US8226959B2 (en) Vaccine compositions
US8124053B2 (en) Compositions comprising chitin microparticles and their medical uses
JP5930146B2 (ja) 免疫刺激オリゴヌクレオチドおよび前記免疫刺激オリゴヌクレオチドを含む治療剤
Ferreira et al. Overview on inhalable nanocarriers for respiratory immunization
CN114765953A (zh) 肺表面活性物质-仿生纳米颗粒的组合物和方法
Ongun et al. ALT ÜNİTE BAZLI AŞILARIN PULMONER UYGULAMASINA GENEL BAKIŞ
Awate Cellular and molecular mechanisms of action of the novel adjuvant polyphosphazene